Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock UpsideBenzinga • 10/17/24
A Market Crash Could Ruin Baby Boomers: 5 Safe High-Yield Dividend Stocks and Advice24/7 Wall Street • 10/16/24
Bristol Myers Squibb (BMY) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research • 10/11/24
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)Business Wire • 10/03/24
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines PipelineBenzinga • 09/30/24
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis PotentialBenzinga • 09/27/24
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)Seeking Alpha • 09/27/24
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World SettingBusiness Wire • 09/27/24
Bristol Myers Squibb shares move higher on FDA approval of schizophrenia drugProactive Investors • 09/27/24
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 DecadesBenzinga • 09/27/24
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline ProgressSeeking Alpha • 09/27/24
Bristol Myers Stock Jumps. Why Approval for Its Schizophrenia Drug Is Ground Breaking.Barrons • 09/27/24